“This is your opinion only.”
Time will show , I will not be surprise with partnership in cancer relatively soon after hold removal.”
Over 2 years ago, in March of 2021, I opined that CD12 had failed based on NP’s wild and ridiculous “send to 100 FDAs” PR. The stock was $4.xx at the time of that PR.
What happened? CD12 failed and the stock dropped to $2. Now it’s .2689.
There is no pending partnership for cancer. The trials were a mix of different doses, different cancers and uncontrolled. They’ll need to complete a phase 2 and have clear data before any partnership is possible.
They’ll also need to clear the books of $65 million owed to Samsung. Yuck.